Entacapone has median FTO IC50 of 3.5 microM.
https://stm.sciencemag.org/content/11/488/eaau7116?rss=1
According to Su et al, Bisantrene has IC50 of 142 nM, i.e. about 25 times more potent.
So, dear @RaceOncology, the questions are:
(a) why has Entacapone not been trialled for cancer?
(b) more relevantly for RAC, why has Bisantrene not been trialled for Parkinsons Disease or other CNS diseases?
Note: In the Sheba trial, CNS disease was an exclusion criterion.
The RAC 3-Pillar Trifecta, page-166
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.83 |
Change
-0.030(1.61%) |
Mkt cap ! $311.7M | |||
| Open | High | Low | Value | Volume |
| $1.86 | $1.91 | $1.79 | $169.3K | 92.02K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 92 | $1.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.87 | 3472 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |